Delhi: Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced that Health Canada has.
UHN stands by its decision to use the drug deferiprone to treat thalassemia. Hospital officials reject allegations that money from Apotex influenced patient care.
UHN stands by its decision to use the drug deferiprone to treat thalassemia. Hospital officials reject allegations that money from Apotex influenced patient care.
Cairo, Egypt: In a new study conducted by Janet L. Kwiatkowski and team, it was seen that deferiprone had acceptable effectiveness and safety profiles, which were similar to those reported in.